Option chain shows key data for Shionogi's stock options at various strike prices and expiration dates. Traders use this information to analyze potential trades and assess market sentiment for Shionogi.

Shionogi (OTC:SGIOY) Stock, Option Chain

Shionogi & Co Ltd is a specialty and generic drug manufacturing company. The company focuses on the manufacturing and distribution of pharmaceuticals, diagnostic reagents, and medical devices. Shionogi engages in manufacturing, formulation, packaging, and analysis as part of its commercialization research that spans late stage drug discovery through commercial production. The company's research and development strategy utilizes partnership and licensing opportunities with academic constituents and venture companies.

Biotech

Earnings

News

Penny Stocks

Offerings

Small Cap

General

ADGI

ADMP

AFMD

Amplify YieldShares Oil Hedged MLP Income ETF

AMLX

BIOC

CALA

GERN

IGMS

INVO

PDSB

REPL

RHHBY

SGIOY

SNOA

SPRO

TSHA

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours.

The Daily Biotech Pulse: Roche&#39;s Lung Cancer Combo Therapy Flunks Late-Stage Study, Adagio Spikes On Positive COVID Antibody Data, Amylyx Awaits Adcom Verdict

Health Care

AVIR

GILD

TOMDF

APLIF

CYDY

Photo by Christina Victoria Craft on Unsplash

Is Pfizer Conceding Race in Hospitalized Covid Because of Todos Medical&#39;s Triple MOA Antiviral?

Guidance

ALDX

ALIM

ALNY

BNTX

BPMC

CDNA

CRVS

EVLO

GNCA

HCWB

IFRX

Laboratory Corporation Of America Holdings

LMAT

MMSI

NVCR

PTCT

RGEN

RPTX

TARO

TVTX

Here&#39;s a roundup of top developments in the biotech space over the last 24 hours:

The Daily Biotech Pulse: Merck Reports Beat-And-Raise Quarter, Pfizer-BioNTech Snag Orders For Additional Vaccine Doses, HCW Cleared For Phase 1 Study Of Pancreatic Cancer Drug

SHIONOGI & CO UNSP/ADR by Shionogi & Co. Ltd.

Shionogi & Co Ltd

AMR Update - Mid-2024

Harding Loevner International Equity Q2 2024 Report

Harding Loevner International Equity ADR Q2 2024 Report

Harding Loevner International Developed Markets Equity Q2 2024 Report

Warning: SGIOY is at high risk of cutting its dividend

Shionogi &amp; Co. reports Q2 results

Shionogi's Xocova effective in preventing symptomatic COVID-19: study

Shionogi & Co., Ltd. (SGIOY) Q2 2024 Earnings Call Transcript

Harding Loevner International Equity ADR Q3 2024 Report

AAGIY

AAIGF

AAUKF

ADYEY

ADYYF

ALFVF

ALIZF

ALIZY

ARIS

ASAZF

ASAZY

ASML

ASMLF

ASPN

BBVA

BBVXF

BHPLF

BMYMP

BNDSF

BNDSY

BRKR

BWMX

CDMO

CDZI

CDZIP

CHGCF

CHGCY

CLPBF

CLPBY

CLSK

COCSF

CSHI

DASTF

DASTY

DAVA

DBSDF

DBSDY

DISPF

DSCSY

GBOOF

GBOOY

GMAB

GNMSF

HLNCF

HRSHF

HSHCY

HXGBF

HXGBY

IFNNF

IFNNY

ISUNQ

LRLCF

LRLCY

MELI

NGLOY

NJDCY

NNDNF

NONOF

NSRGF

NSRGY

NVDA

NVZMF

NVZMY

PATH

PIAIF

PNGAY

QIHCF

RHHBF

RHHVF

SAPGF

SBGSF

SBGSY

SGIOF

SHMDF

SITE

SMNNY

SNEJF

SONVF

SONVY

SONY

SSMXF

SSMXY

TCEHY

TCTZF

TECH

TSMWF

WXIBF

WXXWY

XMTR

XNGSF

XNGSY

Shionogi

Comments

Shionogi

Shionogi (SGIOY) Options

No option chain data available. Please try again later

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga